Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges
- PMID: 17205962
- DOI: 10.1093/ndt/gfl718
Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges
Abstract
Background: Dialysis Outcomes and Practice Patterns Study has shown that the proportion of haemodialysis patients with adequate mineral metabolism parameters according to the Kidney Disease Outcome Quality Initiative (K/DOQI) guidelines is very low. The adequacy of such parameters in relation to the recommended ranges in patients with different chronic kidney disease (CKD) stages has not been reported. The objective of this study is to provide an in-depth description of mineral metabolism in the early stages of CKD in a European population, and to compare it with current recommendations for stages 3-5 (K/DOQI guidelines).
Methods: A total of 1836 patients were classified into stages 1-5 according to K/DOQI guidelines. The following clinical and biochemical data were recorded: age, gender, CKD aetiology, presence of diabetes, serum creatinine, creatinine clearance, serum phosphate, calcium, CaxP product and intact parathyroid hormone (PTH).
Results: A decrease in 1,25-dihydroxyvitamin D and an increase in PTH are the earliest mineral metabolism alterations in CKD, while serum calcium and phosphate are altered later in the course of CKD. The percentages of patients with serum levels within the recommended K/DOQI guidelines for stages 3, 4 and 5 were as follows: serum calcium: 90.7, 85.6 and 55; serum phosphate: 90.9, 77.1 and 70.3; iPTH 42.4, 24.6 and 46.8 and Ca x P product 99.9, 99.6 and 83.8, respectively. The percentages of patients who had all four parameters within the recommended ranges were 34.9, 18.4 and 21.6 for stages 3, 4 and 5, respectively.
Conclusion: Mineral metabolism disturbances start early in the course of CKD. The first alterations to take place are a 1,25-dihydroxyvitamin D decrease, a 24 h urine phosphate decrease and a PTH elevation, which show significant level variation when the glomerular filtration rate falls below 60 ml/min. K/DOQI recommended levels for mineral metabolism parameters are difficult to accomplish, in particular for PTH levels.
Similar articles
-
[CA-P control in haemodialysis and K/DOQI guidelines].Nefrologia. 2006;26(3):351-7. Nefrologia. 2006. PMID: 16892824 Spanish.
-
Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.Nephrol Dial Transplant. 2006 Jun;21(6):1663-8. doi: 10.1093/ndt/gfl006. Epub 2006 Feb 7. Nephrol Dial Transplant. 2006. PMID: 16464885
-
Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.J Nephrol. 2005 Nov-Dec;18(6):739-48. J Nephrol. 2005. PMID: 16358233
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines.Kidney Int Suppl. 2005 Jul;(96):S7-14. doi: 10.1111/j.1523-1755.2005.00449.x. Kidney Int Suppl. 2005. PMID: 15954948 Review.
Cited by
-
Impact of adipose tissue in chronic kidney disease development (Review).Exp Ther Med. 2021 May;21(5):539. doi: 10.3892/etm.2021.9969. Epub 2021 Mar 23. Exp Ther Med. 2021. PMID: 33815612 Free PMC article. Review.
-
A physiologic-based approach to the evaluation of a patient with hyperphosphatemia.Am J Kidney Dis. 2013 Feb;61(2):330-6. doi: 10.1053/j.ajkd.2012.06.026. Epub 2012 Aug 30. Am J Kidney Dis. 2013. PMID: 22938849 Free PMC article.
-
Prognosis and determinants of serum PTH changes over time in 1-5 CKD stage patients followed in tertiary care.PLoS One. 2018 Aug 23;13(8):e0202417. doi: 10.1371/journal.pone.0202417. eCollection 2018. PLoS One. 2018. PMID: 30138402 Free PMC article. Clinical Trial.
-
Calcium balance and negative impact of calcium load in peritoneal dialysis patients.Perit Dial Int. 2014 Jun;34(4):345-52. doi: 10.3747/pdi.2013.00177. Epub 2014 Feb 4. Perit Dial Int. 2014. PMID: 24497596 Free PMC article. Review.
-
Sclerostin as a new key factor in vascular calcification in chronic kidney disease stages 3 and 4.Int Urol Nephrol. 2016 Dec;48(12):2043-2050. doi: 10.1007/s11255-016-1379-8. Epub 2016 Jul 27. Int Urol Nephrol. 2016. PMID: 27465794
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical